π¬ Ubiquitin code unlocks new drug frontiers
Protein-degrading drugs, leveraging the cellβs ubiquitin system, are revolutionizing medicine. FDA approved Veppanu for breast cancer and Zenbexus for multiple myeloma in May and August this year. These drugs use ubiquitin, a small protein, to selectively destroy problematic proteins within cells. Understanding the complex 'ubiquitin code' is helping design targeted therapies for cancer and more. Researchers anticipate a major shift in the pharmaceutical industry due to this research. π§¬